• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    FIGS (FIGS) Is Up 31.1% After Raising 2026 Revenue Guidance And Buybacks Expansion - Has The Bull Case Changed?

    Simply Wall St·08/10/2026 11:23:44
    Listen to the news
    • In early August 2026, FIGS, Inc. reported second quarter sales of US$196.62 million and net income of US$28.38 million, alongside raised full-year 2026 revenue growth guidance and an expanded share repurchase authorization to US$200 million.
    • The combination of stronger profitability, higher growth expectations, and continued buybacks suggests management is doubling down on confidence in FIGS’ operating and capital allocation approach.
    • We’ll now examine how this upgraded full-year revenue outlook reframes FIGS’ existing investment narrative around growth, margins, and capital returns.

    Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    FIGS Investment Narrative Recap

    To own FIGS, you need to believe its direct to consumer medical apparel brand can keep expanding while protecting margins against rising costs and competition. Right now, the key near term catalyst is whether FIGS can sustain healthy growth without leaning heavily on promotions. The biggest risk remains cost pressure from tariffs and sourcing concentration, which this quarter’s strong results and higher guidance do not remove, but may make investors more patient about.

    The most relevant announcement here is FIGS lifting its 2026 net revenue outlook to about 20% growth versus 2025. That upgrade directly affects how investors think about the growth side of the story, especially after a quarter where sales reached US$196.62 million and net income was US$28.38 million. It sharpens the focus on whether FIGS can keep scaling responsibly while managing tariff exposure, product mix, and international expansion without sacrificing profitability.

    Yet against this optimism, investors should still watch how exposed FIGS is to trade friction and tariff costs...

    Read the full narrative on FIGS (it's free!)

    FIGS' narrative projects $862.6 million revenue and $77.4 million earnings by 2029. This requires 9.0% yearly revenue growth and a $36.8 million earnings increase from $40.6 million today.

    Uncover how FIGS' forecasts yield a $17.62 fair value, a 24% upside to its current price.

    Exploring Other Perspectives

    FIGS 1-Year Stock Price Chart
    FIGS 1-Year Stock Price Chart

    Some of the lowest ranked analysts paint a much tougher picture than consensus, assuming revenue of about US$887.4 million and earnings of US$72.2 million by 2029, which may look conservative in light of the latest upgrades, so it is worth comparing their more cautious expectations with your own view of FIGS’ growth and risk profile.

    Explore 5 other fair value estimates on FIGS - why the stock might be worth as much as 54% more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your FIGS research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free FIGS research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate FIGS' overall financial health at a glance.

    No Opportunity In FIGS?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.